Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARAV NASDAQ:CKPT NASDAQ:MLND NASDAQ:MRKR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVARAVIVE$0.04$0.04$0.04▼$2.46N/AN/AN/AN/ACKPTCheckpoint Therapeutics$4.26$4.23$2.06▼$4.50$370.71M1.181.56 million shsN/AMLNDMillendo Therapeutics$9.58-4.9%$4.00$0.92▼$16.95$182.43M0.481.52 million shs36,284 shsMRKRMarker Therapeutics$0.95-0.1%$1.24$0.81▼$5.95$12.28M1.52788,394 shs87,406 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVARAVIVE0.00%0.00%0.00%0.00%0.00%CKPTCheckpoint Therapeutics0.00%0.00%0.00%0.00%+69.05%MLNDMillendo Therapeutics+1.51%-8.45%-4.37%+45.94%+566.89%MRKRMarker Therapeutics-4.47%+4.52%-21.46%-35.35%-65.94%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVARAVIVE$0.04$0.04$0.04▼$2.46N/AN/AN/AN/ACKPTCheckpoint Therapeutics$4.26$4.23$2.06▼$4.50$370.71M1.181.56 million shsN/AMLNDMillendo Therapeutics$9.58-4.9%$4.00$0.92▼$16.95$182.43M0.481.52 million shs36,284 shsMRKRMarker Therapeutics$0.95-0.1%$1.24$0.81▼$5.95$12.28M1.52788,394 shs87,406 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVARAVIVE0.00%0.00%0.00%0.00%0.00%CKPTCheckpoint Therapeutics0.00%0.00%0.00%0.00%+69.05%MLNDMillendo Therapeutics+1.51%-8.45%-4.37%+45.94%+566.89%MRKRMarker Therapeutics-4.47%+4.52%-21.46%-35.35%-65.94%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAVARAVIVE 0.00N/AN/AN/ACKPTCheckpoint Therapeutics 2.33Hold$4.331.72% UpsideMLNDMillendo Therapeutics 0.00N/AN/AN/AMRKRMarker Therapeutics 3.50Strong Buy$13.171,287.43% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAVARAVIVE$9.14MN/AN/AN/AN/AN/ACKPTCheckpoint Therapeutics$41K9,041.59N/AN/A($0.47) per share-9.06MLNDMillendo TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AMRKRMarker Therapeutics$6.59M1.86N/AN/A$1.73 per share0.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAVARAVIVE-$76.32MN/A0.00∞N/AN/AN/AN/AN/ACKPTCheckpoint Therapeutics-$51.85M-$1.29N/A∞N/AN/AN/A-659.07%N/AMLNDMillendo Therapeutics-$36.41MN/A0.00∞N/AN/A-91.03%-72.44%N/AMRKRMarker Therapeutics-$10.73M-$1.37N/AN/AN/A-271.12%-114.59%-90.31%11/13/2025 (Estimated)Latest CKPT, MRKR, ARAV, and MLND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MRKRMarker Therapeutics-$0.55-$0.29+$0.26-$0.29$0.72 million$0.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARAVARAVIVEN/AN/AN/AN/AN/ACKPTCheckpoint TherapeuticsN/AN/AN/AN/AN/AMLNDMillendo TherapeuticsN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAVARAVIVEN/AN/AN/ACKPTCheckpoint TherapeuticsN/A0.290.29MLNDMillendo TherapeuticsN/A6.396.39MRKRMarker TherapeuticsN/A3.453.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAVARAVIVE35.80%CKPTCheckpoint Therapeutics22.00%MLNDMillendo TherapeuticsN/AMRKRMarker Therapeutics22.39%Insider OwnershipCompanyInsider OwnershipARAVARAVIVE60.40%CKPTCheckpoint Therapeutics2.10%MLNDMillendo TherapeuticsN/AMRKRMarker Therapeutics7.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAVARAVIVE20N/AN/ANo DataCKPTCheckpoint Therapeutics1087.02 million47.81 millionOptionableMLNDMillendo Therapeutics1219.04 millionN/ANot OptionableMRKRMarker Therapeutics6012.94 million11.93 millionNot OptionableCKPT, MRKR, ARAV, and MLND HeadlinesRecent News About These CompaniesMarker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 28, 2025 | globenewswire.comMarker Therapeutics (MRKR) Falls 20.6% After Positive Clinical StudyAugust 27, 2025 | insidermonkey.comMarker Therapeutics stock soars on promising Phase 1 lymphoma study dataAugust 26, 2025 | investing.comMarker Therapeutics provides update on observations from Phase 1 APOLLO studyAugust 26, 2025 | msn.comMarker Therapeutics Stock Drops After Report About Lymphoma TreatmentAugust 26, 2025 | benzinga.comMarker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed LymphomaAugust 26, 2025 | globenewswire.comMarker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth ConferenceJuly 30, 2025 | globenewswire.comMarker Therapeutics Insider Trading Activity | NASDAQ:MRKR | BenzingaJuly 18, 2025 | benzinga.comHere's Why We're Watching Marker Therapeutics' (NASDAQ:MRKR) Cash Burn SituationJuly 11, 2025 | finance.yahoo.comMarker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with LymphomaJune 17, 2025 | globenewswire.comMarker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with LymphomaMay 20, 2025 | globenewswire.comMarker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell TherapiesMay 19, 2025 | globenewswire.comArkansas Historic Preservation Program hosts National Historic Marker WeekendApril 17, 2025 | stuttgartdailyleader.comSMarker Therapeutics (MRKR) Receives a Buy from Canaccord GenuityApril 1, 2025 | markets.businessinsider.comMarker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology ConferenceApril 1, 2025 | markets.businessinsider.comMarker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology ConferenceApril 1, 2025 | globenewswire.comMarker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last yearMarch 31, 2025 | markets.businessinsider.comMarker Therapeutics Reports Year-End 2024 Corporate and Financial ResultsMarch 31, 2025 | globenewswire.comMarker Therapeutics stockholder vote clears warrant issuanceMarch 28, 2025 | investing.comMarker Therapeutics initiated with a Buy at CanaccordMarch 5, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCKPT, MRKR, ARAV, and MLND Company DescriptionsARAVIVE NASDAQ:ARAV$0.04 0.00 (0.00%) As of 09/17/2025Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Checkpoint Therapeutics NASDAQ:CKPTCheckpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Millendo Therapeutics NASDAQ:MLNDAs of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.Marker Therapeutics NASDAQ:MRKR$0.95 0.00 (-0.14%) As of 12:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Nike’s Red-Hot Analyst Buzz: Is a Comeback Brewing? Is Netflix's Ad Deal With Amazon the Catalyst for a New Uptrend? DoorDash Buys Deliveroo: A Game Changer? The Side of Rate Cuts Nobody Is Telling You About Broadcom Hits Record High After CEO Hock Tan AI Pay Package CrowdStrike Stock Set for Breakout as Agentic AI Demand Surges Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
